These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 1362517)
1. Postnatal lead exposure induces supersensitivity to the stimulus properties of a D2-D3 agonist. Cory-Slechta DA; Pokora MJ; Widzowski DV Brain Res; 1992 Dec; 598(1-2):162-72. PubMed ID: 1362517 [TBL] [Abstract][Full Text] [Related]
2. Low level lead exposure increases sensitivity to the stimulus properties of dopamine D1 and D2 agonists. Cory-Slechta DA; Widzowski DV Brain Res; 1991 Jul; 553(1):65-74. PubMed ID: 1681979 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the interaction between D1 and D2 receptors in a drug discrimination paradigm. Williams JE; Sutherland JV; Woolverton WL Behav Neural Biol; 1990 May; 53(3):378-92. PubMed ID: 1972014 [TBL] [Abstract][Full Text] [Related]
4. Lead-induced changes in dopamine D1 sensitivity: modulation by drug discrimination training. Cory-Slechta DA; Pokora MJ; Fox RA; O'Mara DJ Neurotoxicology; 1996; 17(2):445-57. PubMed ID: 8856740 [TBL] [Abstract][Full Text] [Related]
5. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
7. The D2 agonist quinpirole potentiates the discriminative stimulus effects of the D1 agonist SKF 38393. Williams JE; Woolverton WL Pharmacol Biochem Behav; 1990 Oct; 37(2):289-93. PubMed ID: 1981936 [TBL] [Abstract][Full Text] [Related]
8. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. LaHoste GJ; Marshall JF Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762 [TBL] [Abstract][Full Text] [Related]
9. Apparent mediation of the stimulus properties of a low dose of quinpirole by dopaminergic autoreceptors. Widzowski DV; Cory-Slechta DA J Pharmacol Exp Ther; 1993 Aug; 266(2):526-34. PubMed ID: 8355188 [TBL] [Abstract][Full Text] [Related]
10. The effects of dopamine agonists on fixed interval schedule-controlled behavior are selectively altered by low-level lead exposure. Cory-Slechta DA; Pokora MJ; Preston RA Neurotoxicol Teratol; 1996; 18(5):565-75. PubMed ID: 8888021 [TBL] [Abstract][Full Text] [Related]
11. Behavioral differentiation of the stimulus properties of a dopaminergic D1 agonist from a D2 agonist. Cory-Slechta DA; Widzowski DV; Newland MC J Pharmacol Exp Ther; 1989 Sep; 250(3):800-8. PubMed ID: 2789282 [TBL] [Abstract][Full Text] [Related]
12. Depression of the monosynaptic reflex by apomorphine or bromocriptine is not mediated by D1/D2 receptors. Kamijo N; Nagao T; Ono H Neuropharmacology; 1993 Aug; 32(8):777-83. PubMed ID: 8105410 [TBL] [Abstract][Full Text] [Related]
15. Alpha 1 (but not alpha 2)-adrenoceptor agonists in combination with the dopamine D2 agonist quinpirole produce locomotor stimulation in dopamine-depleted mice. Eshel G; Ross SB; Kelder D; Edis LE; Jackson DM Pharmacol Toxicol; 1990 Aug; 67(2):123-31. PubMed ID: 1979437 [TBL] [Abstract][Full Text] [Related]
16. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists. Pellissier G; Demenge P J Cardiovasc Pharmacol; 1991 Oct; 18(4):548-55. PubMed ID: 1724532 [TBL] [Abstract][Full Text] [Related]
17. Effects of dopaminergic drugs on working and reference memory in rats. Bushnell PJ; Levin ED Pharmacol Biochem Behav; 1993 Aug; 45(4):765-76. PubMed ID: 8105486 [TBL] [Abstract][Full Text] [Related]